Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases

作者：Ananthakrishnan, Ashwin N.; Luo, Chengwei; Yajnik, Vijay; Khalili, Hamed; Garber, John J.; Stevens, Betsy W.; Cleland, Thomas; Xavier, Ramnik J.^*

来源：Cell Host & Microbe, 2017, 21(5): 603-+.

DOI：10.1016/j.chom.2017.04.010

• ONSET CROHNS-DISEASE
• ULCERATIVE-COLITIS
• RHEUMATOID-ARTHRITIS
• PSORIATIC-ARTHRITIS
• ANTIBIOTICS
• BUTYRATE
• BURDEN
• MANAGEMENT
• ALIGNMENT
• COHORT

The gut microbiome plays a central role in inflammatory bowel diseases (IBDs) pathogenesis and propagation. To determine whether the gut microbiome may predict responses to IBD therapy, we conducted a prospective study with Crohn's disease (CD) or ulcerative colitis (UC) patients initiating anti-integrin therapy (vedolizumab). Disease activity and stool metagenomes at baseline, and weeks 14, 30, and 54 after therapy initiation were assessed. Community a-diversity was significantly higher, and Roseburia inulinivorans and a Burkholderiales species were more abundant at baseline among CD patients achieving week 14 remission. Several significant associations were identified with microbial function; 13 pathways including branched chain amino acid synthesis were significantly enriched in baseline samples from CD patients achieving remission. A neural network algorithm, vedoNet, incorporating microbiome and clinical data, provided highest classifying power for clinical remission. We hypothesize that the trajectory of early microbiome changes may be a marker of response to IBD treatment.

• 出版日期2017-5-10